Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1103-1116

  Gonsette, Richard E ^a  

^a National Multiple Sclerosis Center   (Belgium)

Author keywords

Alemtuzumab; Fingolimod; Immunosuppressant; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

ALEMTUZUMAB; ALPHA4 INTEGRIN; ANTHRACENE DERIVATIVE; BETA INTERFERON; BETA1 INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DNA TOPOISOMERASE (ATP HYDROLYSING); FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR; ISOXAZOLE DERIVATIVE; LAQUINIMOD; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; NATALIZUMAB; PIXANTRONE; PLACEBO; RAZOXANE; RITUXIMAB; ROQUINIMEX; TERIFLUNOMIDE; TGN 1412; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BLOOD PRESSURE; BRADYCARDIA; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CELL COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISABILITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEMATOLOGIC DISEASE; HEMIANOPIA; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTE; LYMPHOCYTE RECIRCULATION; MENSTRUATION DISORDER; MONOCYTE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYELODYSPLASIA; OFF LABEL DRUG USE; PLASMAPHERESIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CLADRIBINE; CYCLOPHOSPHAMIDE; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LIGANDS; MITOXANTRONE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 34250687536     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1103     Document Type: Review

References (119)

1. COLES AJ, COX A, LE PAGE E et al.: The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J. Neurol. (2006) 253:98-108.
2. FOX EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther. (2006) 28:461-474.
3. HARTUNG LIP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 360:2018-2025.
4. MERGENTHALER HG, BRUHL P, EHNINGER G, HEIDEMANN E: Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Cancer Chemother. Pharmacol. (1987) 20:8-12.
5. STEWART Dj, GREEN RM, MIKHAEL NZ, MONTPETIT V, THIBAULT M, NLAROUN JA: Human autopsy tissue concentrations of mitoxantrone. Cancer Treat. Rep. (1986) 70:1255-1261.
6. NEUHAUS O, KIESEIER BC, HARTUNG HP: Mitoxantrone in multiple sclerosis. Adv. Neurol. (2006) 98:293-302.
7. GBADAMOSI J, BUHMANN C, TESSMER W, MOENCH A, HAAG F, HEESEN C: Effects of mitoxantrone on multiple sclerosis pacients' lymphocyte subpopulations; and production of immunoglobulin, TNF-alpha and IL-10. Eur. Neurol. (2003) 49:137-141.
8. CHAN A, WEILBACH FX, TOYKA KV, GOLD R: Mitoxantrone induces cell death in peripheral blood lymphocytes of multiple sclerosis patients. Clin. Exp. Immunol. (2005) 139:152-158.
9. PUTZKI N, KUMAR M, VAGO S, KREUTZFELDER E, LIMMROTH V: Mitoxantrone treatment leads to a persistent and selective decrease of the B cell count in patients with multiple sclerosis. Neurology (2006) 66(Suppl. 2):A370. Abstract P06.160.
10. NEUHAUS O, WIENDL H, KIESEIER BC et al.: Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J. Neuroimmunol. (2005) 168:128-137.
11. JEFFERY DR, LEFKOVITZ DS, CRITTENDEN JP: Treatment of Marburg variant multiple sclerosis with mitoxantrone. J. Neuroimaging (2004) 14:58-62.
12. WEINSTOCK-GUTTMAN B, RAMANATHAN M, LINCOFF N et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. (2006) 63:957-963.
13. KOPADZE T, DEHMEL T, HARTUNG HP, STUVE O, KIESEIER BC: Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch. Neurol. (2006) 63:1572-1578.
14. ANGELUCCI F, MIRABELLA M, CAGGIULA M et al.: Effect of mitoxantrone on cytokine and BDNF production by peripheral blood mononuclear cells in secondary progressive multiple sclerosis patients. Neurology (2006) 64(Suppl.):A195. Abstract P03.126.
15. CORREALE J, RUSH C, AMENGUAL A, GOICOCHEA MT. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J. Neuroimmunol. (2005) 162:173-183.
16. GONSETTE RE: Mitoxantrone in progressive multiple sclerosis: when and how to creat? J. Neurol. Sci. (2003) 206:203-208.
17. KRAPF H, MAUCH E, FETZER U, LAUFEN H, KORNHUBER HH: Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology (1995) 37:113-119.
18. EDAN G, MILLER D, CLANET M et al.: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry (1997) 62:112-118.
19. ZINGLER VC, STRUPP M, JAHN K, GROSS A, HOHLFELD R, BRANDT T: The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients. Nervenarzt (2005) 76:740-747.
20. JEFFERY DR, CHEPURI N, DURDEN D, BURDETTE J: A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult. Scler. (2005) 11:296-301.
21. OSTBERG A, PITTAS F, TAYLOR B: Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. Intern. Med. J. (2005) 35:382-387.
22. LE PAGE E, LERAY E, TAURIN G, COUSTANS M, CHAPERON J, EDAN G: Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients. Rev. Neurol. (2006) 162:185-194.
23. DEBOUVERIE M, VANDENBERGHE N, MORRISSEY SP et al.: Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Mult. Scler. (2004) 10:407-412.
24. BENNET R, AL-SABBAGH A: Continuing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis: the RENEW study. Neurology (2006) 66(Suppl. 2):A20. Abstract P01.068.
25. LE PAGE E, LERAY E, CHAPERON J, EDAN G: 5-year follow-up after mitoxantrone treatment start: an observational study of 100 consecutive patients with aggressive relapsing remitting multiple sclerosis. Neurology (2006) 66(Suppl. 2):A33. Abstract P01.082.
26. LE PAGE E, LERAY E, BROCHET B: Safety profile of mitoxantrone in a french cohort of 802 multiple sclerosis patients: a 5-years follow-up study. Neurology (2006) 66(Suppl. 2):A63. Abstract S02.006.
27. LEIST TP, GALLARDO S, HARTNETT K, KALMAN B: Monitoring of cardiac function during mitoxantrone therapy. Neurology (2005) 64(Suppl. 1):Abstract P05.140.
28. OLINDO S, GUILLON B, HELIAS J, PHILLIBERT B, MAGNE C, FEVE JR: Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur. J. Neurol. (2002) 9:287-291.
29. PAUL F, DORR J, WURFEL J, VOGEL HP, ZIPP F: Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (2007) 78:198-200.
30. HUETTEMANN E, SAKKA SG: Anaesthesia and anti-cancer chemotherapeutic drugs. Curr. Opin. Anaesthesiol. (2005) 18:307-314.
31. GOFFETTE S, VAN PESCH V, VANOVERSCHELDE JL, MORANDINI E, SINDIC CJ: Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J. Neurol. (2005) 252:1217-1222.
32. PATTONERI R PELA G, MONTANARI E, PESCI I, MORUZZI P, BORGHETTI A: Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxiciry in patients with multiple sclerosis. Eur. J. Echocardiogr. (2007) 8:144-150.
33. HERMAN EH, ZHANG J, RIFAI N: The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and micoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. (2001) 48:297-304.
34. BERNITSAS E, WEI W, MIKOL DD: Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann. Neurol. (2006) 59:206-209.
35. GIESELER F, CLARK M, STIEBELING K, PUSCHMANN M, VALSAMAS S: Induction of apoptosis by idarubicin: how important is the plasma peak? Int. J. Clin. Pharmacol. Ther. (2000) 38:217-221.
36. MARIKO K, CHOW E, REED D: A pilot study of mitoxantrone plus derazoxane versus mitoxantrone in patients with relapsing remitting, secondary progressive and progressive relapsing MS. Neurology (2005) 64(Suppl. 1):A330. Abstract P05.139.
37. GHALIE RG, MAUCH E, EDAN G et al.: A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. (2002) 8:441-445.
38. VICARI AM, CICERI F, FOLLI F et al.: Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia (1998) 12:441-442
39. BRASSAT D, RECHER C, WAUBANT E et al.: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 59:954-955.
40. TANASESCU R, DEBOUVERIE M, PITTION S, ANXIONNAT R, VESPIGNANI H: Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J. Neurol. (2004) 251:762-763.
41. HEESEN C, BRUEGMANN M, GBDAMOSI J, KOCH E, MONCH A, BUHMANN C: Therapy-related acute myclogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult. Scler. (2003) 9:213-214.
42. CATTANEO C, ALMICI C, BORLENGHI E, MOTTA M, ROSSI G: A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia (2003) 17:985-986.
43. MOGENET I, SIMIAND-ERDOCIAIN E, CANONGE JM, PRIS J: Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann. Pharmacother. (2003) 37:747-748.
44. DELISSE B, DE SEZE J, MACKOWIAK A et al.: Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult. Scler. (2004) 10:92.
45. VOLTZ R, STARCK M, ZINGLER V, STRUPP M, KOLB HJ: Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult. Scler. (2004) 10:472-474.
46. NOVOSELAC AV, REDDY S, SANMUGARAJAH J: Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia (2004) 18:1561-1562.
47. RAMTAHAL J, JACOB A, DAS K, BOGGILD M: 5-year retrospective study of the use of mitoxantrone and glatiramer acetate combination in patients with very active relapsing remitting multiple sclerosis. Neurology (2005) 64(Suppl. 1):A387. Abstract P06.163.
48. TELLEZ N, RIO J, TINTORE M et al.: Mitoxantrone in MS patients, non-responders to interferon. Mult. Scler. (2005) 11(Suppl. 1) S172. Abstract P648.
49. ARRUDA WO, MONTU MB, DE OLIVEIRA M DE S, RAMINA R: Acute mycloid leukaemia induced by mitoxantrone: case report. Arq. Neuropsiquiatr (2005) 63:327-329.
50. NOLLET S, BERGER E, DECONINCK E, BALDAUF E, RUMBACH L: Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone. Rev. Neurol. (2006) 162:195-199.
51. LYNN DJ, BLUM W, CATALAND S, RAMMOHAN KW. Multiple sclerosis and mitoxantrone treatment-related leukaemia. A single center experience. Neurology (2006) 66(Suppl. 2):A31. Abstract P01.074.
52. LEDDA A, CAOCCI G, SPINICCI G, COCCO E, MAMUSA E, NASA GL: Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia (2006) 20:2217-2218.
53. JASTER JH, NIELL HB, DOHAN FC, SMITH TW. Therapy-related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with MS. Neurology (2003) 60:1399-1400.
54. KRAPCHO AP, LANDI JJ, HACKER MP, MCCORMACK JJ: Synthesis and antineoplastic evaluations of 5,8-bis[(aminoalkyl)amino]- I -azaanthracen e-9,10-diones. J. Med. Chem. (1985) 28:1124-1126.
55. GONSETTE RE, DUBOIS B: Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J. Neurol. Sci. (2004) 223:81-86.
56. CAVALETTI G, CAVALLETTI E, CRIPPA L et al.: Pixantrone (BBR2778) reduces the severity ofexperimental allergic encephalomyelitis. J. Neuroimmunol. (2004) 151:55-65.
57. MAZZANTI B, BIAGIOLI T, ALDINUCCI A et al.: Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. J. Neuroimmunol. (2005) 168:111-117.
58. WEINER HL: Immunosuppressive treatment in multiple sclerosis. J. Neurol. Sci. (2004) 223:1-11.
59. KILLIAN JM, BRESSLER RB, ARMSTRONG RM, HUSTON DP: Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch. Neurol. (1988) 45:27-30.
60. GOBBINI MI, SMITH ME, RICHERT ND, FRANK JA, MCFARLAND HF: Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sderosis. J. Neuroimmunol. (1999) 99:142-149.
61. HOHOL MJ, OLEK MJ, ORAV EJ et al.: Treatment of progressive multiple sclerosis with pulse cyclophosphafnide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult. Scler. (1999) 5:403-409.
62. LA MANTIA L, MILANESE C, MASCOLI N, D'AMICO R, WEINSTOCK-GUTTMAN B: Cyclophosphamide for multiple sclerosis. Cochrane Database Syst. Rev. (2007):CD002819.
63. GLADSTONE DE, ZAMKOFF KW, KRUPP L et al.: High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch. Neurol. (2006) 63:1388-1393.
64. KRISHNAN C, DRACHMAN D, MCARTHUR J et al.: High-dose cyclophosphamide in the treatment of aggressive multiple sclerosis. Neurology (2006) 66(Suppl. 2):A30. Abstract P01.072.
65. PERINI P, CALABRESE M, TIBERIO M, RANZATO E BATTISTIN L, GALLO P: Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J. Neurol. (2006) 253:1034-1040.
66. CAON C, DIN M, MADAK S, TSELIS A, LISAK R, KHAN O: Two year open-label observational study comparing monthly intravenous cyclophosphamide and every three month iv mitoxantrone in worsening MS patients. Neurology (2005) 64(Suppl. 1):A329. Abstract P05.137.
67. SELBY R, BRANDWEIN J, O'CONNOR P: Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can. J. Neurol. Sci. (1998) 25:295-299.
68. SIPE JC: Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. (2005) 5:721-727.
69. FILIPPI M, ROVARIS M, IANNUCCI G, MENNEA S, SORMANI MP, COMI G: Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology (2000) 55:1714-1718.
70. BROUSIL JA, ROBERTS RJ, SCHLEIN AL: Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann. Pharmacother. (2006) 40:1814-1821.
71. NOSEWORTHY JH, WOLINSKY JS, LUBLIN FD et al.: Linomide in relapsing and secondary progressive MS: part 1: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 54:1726-1733.
72. TAN IL, LYCKLAMA A NIJEHOLT GJ, POLMAN CH, ADER HJ, BARKHOF F: Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler. (2000) 6:99-104.
73. O'CONNOR PW, LI D, FREEDMAN MS et al.: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 66:894-900.
74. RUNSTROM A, LEANDERSON T, OHLSSON L, AXELSSON B: Inhibition ofthe development ofchronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J. Neuroimmunol. (2006) 173:69-78.
75. POLMAN C, BARKHOF F, SANDBERG-WOLLHEIM M, LINDE A, NORDLE O, NEDERMAN T: Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology (2005) 64:987-991.
76. MONSON NL, CRAVENS PD, FROHMAN EM, HAWKER K, RACKE MK: Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. (2005) 62:258-264.
77. STUVE O, CEPOK S, ELIAS B et al.: Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. (2005) 62:1620-1623.
78. PETEREIT HF, RUBBERT A: Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch. Neurol. (2005) 62:1641-1642.
79. CREE BA, LAMB S, MORGAN K, CHEN A, WAUBANT E, GENAIN C: An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 64:1270-1272.
80. COLES AJ, WING MG, MOLYNEUX P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. (1999) 46:296-304.
81. ROSE JW, WATT HE, WHITE AT, CARLSON NG: Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. (2004) 56:864-867.
82. BIELEKOVA B, RICHERT N, HOWARD T et al.: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA (2004) 101:8705-8708.
83. BIELEKOVA B, CATALFAMO M, REICHERT-SCRIVNER S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA (2006) 103:5941-5946.
84. STUVE O, MARRA CM, JEROME KR et al.: Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol (2006) 59:743-747.
85. DELOIRE MS, TOUIL T, BROCHET B, DOUSSET V, CAILLE JM, PETRY KG: Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult. Scler (2004) 10:540-548.
86. NIINO M, BODNER C, SIMARD ML et al.: Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. (2006) 59:748-754.
87. POLMAN CH, O'CONNOR PW, HAVRDOVA E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:899-910.
88. RUDICK RA, STUART WH, CALAB RESI PA et al.: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:911-923.
89. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:362-368.
90. HEMMER B, FROHMAN E, HARTUNG HP, STUVE O: Central nervous system infections - a potential complication of systemic immunotherapy. Curr. Opin. Neurol. (2006) 19:271-276. Interesting review of potential opportunistic infections after immunosuppressive treatments.
91. VOLLMER TL, PHILLIPS JT, GOODMAN AD et al.: An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult. Scler. (2004) 10:511-520.
92. STUVE O, MARRA CM, BAR-OR A et al.: Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. (2006) 63:1383-1387.
93. GASNAULT J, KAHRAMAN M, DE GOER DE HERVE MG, DURALI D, DELFRAISSY JE TAOUFIK Y: Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS (2003) 17:1443-1449.
94. DU PASQUIER RA, STEIN MC, LIMA MA et al.: JC virus induces a vigorous CD8(+) cytotoxic T cell response in multiple sclerosis patients. J. Neuroimmunol. (2006) 176:181-186.
95. GONZALEZ-AMAR0 R, MITTELBRUNN M, SANCHEZ-MADRID F: Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? Immunology (2005) 116:289-296.
96. KERFOOT SM, NORMAN MU, LAPOINTE BM, BONDER CS, ZBYTNUIK L, KUBES P: Reevaluation of P-selectin and alpha4 incegrin as targets for the treatment of experimental autoimmune encephalomyelitis. J. Immunol. (2006) 176:6225-6234.
97. ENGELHARDT B, RANSOHOFF RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. (2005) 26:485-495.
98. SABATH BF, MAJOR EO: Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J. Infect Dis. (2002) 186(Suppl. 2):S180-S186.
99. FUJII R, KANAI T, NEMOTO Y et al. FTY720 suppresses CD4+CD44highCD62L-effector memory T cell-mediated colitis. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) 291:G267-G274.
100. SAWICKA E, DUBOIS G, JARAI G et al.: The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/ CD25+ T-regulatory cells and enhances their functional activity. J. Immunol. (2005) 175:7973-7980.
101. ISOYAMA N, TAKAI K, TSUCHIDA M, MATSUMURA M, NAITO K: Evidence that FTY720 induces rat thymocyte apoptosis. Transpl. Immunol. (2006) 15:265-271.
102. PAUGH SW CASSIDY MP, HE H et al.: Sphingosine and is analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyllethyl)-1,3-pro panediol, interact with the CB1 cannabinoid receptor. Mol. Pharmacol. (2006) 70:41-50.
103. BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4:1019-1025.
104. LAN YY, DE CREUS A, COLVIN BL et al.: The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am. J. Transplant. (2005) 5;2649-2659.
105. MULLER H, HOFER S, KANEIDER N et al.: The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. (2005) 35:533-545.
106. FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305:70-77.
107. RAUSCH M, HIESTAND P, FOSTER CA, BAUMANN DR, CANNET C, RUDIN M: Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging (2004) 20:16-24.
108. KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355:1124-1140.
109. O'CONNOR P, ANTEL J, COMI G et al.: Oral FTY720 in relapsing MS: results of the dose-blinded, active drug extension phase of a Phase II study. Neurology (2006) 66(Suppl. 2):A123. Abstract S12.003.
110. TEDESCO SILVA H, PINHEIRO MACHADO P, ROSSO FELIPE C, MEDINA PESTANA JO: Immunotherapy for de novo renal transplantation: what's in the pipeline? Drugs (2006) 66:1665-1684.
111. BJURSTEN M, BLAND PW, WILLEN R, HORNQUIST EH: Long-term treatment with anti-alpha 4 integrin antibodies aggravates colitis in G alpha i2-deficient mice. Eur. J. Immunol. (2005) 35:2274-2283.
112. TAKAI K, TAKAHARA S, ISOYAMA N et al.: Effects of FTY720 on rat lymphoid organs. Transplant Proc. (2004) 36:2453-2456.
113. BEYERSDORF N, GAUPP S, BALBACH K et al.: Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. (2005) 202:445-455.
114. SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412. N. Engl. J. Med. (2006) 355:1018-1028.
115. DE SANTIS M, STRAFACE G, CAVALIERE AF, ROSATI P, BATOCCHI AP, CARUSO A: The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology (2006) Epub ahead of print.
116. BERGER JR, HOUFF S: Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. (2006) 28:299-305.
117. STUVE O, MARRA CM, CRAVENS PD et al.: Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch. Neurol. (2007) 64:169-176.
118. HAN S, ZHANG X, WANG G et al.: FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood (2004) 104:4129-4133.
119. PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B, BRINKMANN V, HENGARTNER H, ZINKERNAGEL RM: FTY720 Immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. (2000) 164:5761-5770.